Cardio3 BioSciences SA - Product Pipeline Review - 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 23 pages

Cardio3 BioSciences SA - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Cardio3 BioSciences SA - Product Pipeline Review - 2014’, provides an overview of the Cardio3 BioSciences SA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cardio3 BioSciences SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cardio3 BioSciences SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cardio3 BioSciences SA’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Cardio3 BioSciences SA’s pipeline products

Reasons to buy

- Evaluate Cardio3 BioSciences SA’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cardio3 BioSciences SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cardio3 BioSciences SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cardio3 BioSciences SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cardio3 BioSciences SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cardio3 BioSciences SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Table of Contents

Cardio3 BioSciences SA Snapshot 4
Cardio3 BioSciences SA Overview 4
Key Information 4
Key Facts 4
Cardio3 BioSciences SA - Research and Development Overview 5
Key Therapeutic Areas 5
Cardio3 BioSciences SA - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Cardio3 BioSciences SA - Pipeline Products Glance 9
Cardio3 BioSciences SA - Late Stage Pipeline Products 9
Phase III Products/Combination Treatment Modalities 9
Cardio3 BioSciences SA - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Cardio3 BioSciences SA - Drug Profiles 11
C3BSCQR-1 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
C3BSGQR-1 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
C3BSGQR-4 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Cardio3 BioSciences SA - Pipeline Analysis 15
Cardio3 BioSciences SA - Pipeline Products by Route of Administration 15
Cardio3 BioSciences SA - Pipeline Products by Molecule Type 16
Cardio3 BioSciences SA - Recent Pipeline Updates 17
Cardio3 BioSciences SA - Dormant Projects 20
Cardio3 BioSciences SA - Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23

List of Tables
Cardio3 BioSciences SA, Key Information 4
Cardio3 BioSciences SA, Key Facts 4
Cardio3 BioSciences SA - Pipeline by Indication, 2014 6
Cardio3 BioSciences SA - Pipeline by Stage of Development, 2014 7
Cardio3 BioSciences SA - Monotherapy Products in Pipeline, 2014 8
Cardio3 BioSciences SA - Phase III, 2014 9
Cardio3 BioSciences SA - Preclinical, 2014 10
Cardio3 BioSciences SA - Pipeline by Route of Administration, 2014 15
Cardio3 BioSciences SA - Pipeline by Molecule Type, 2014 16
Cardio3 BioSciences SA - Recent Pipeline Updates, 2014 17
Cardio3 BioSciences SA - Dormant Developmental Projects,2014 20

List of Figures
Cardio3 BioSciences SA - Pipeline by Top 10 Indication, 2014 6
Cardio3 BioSciences SA - Pipeline by Stage of Development, 2014 7
Cardio3 BioSciences SA - Monotherapy Products in Pipeline, 2014 8
Cardio3 BioSciences SA - Pipeline by Top 10 Molecule Type, 2014 16
Companies Mentioned

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

World Therapy: Fibromyalgia – Pipeline Review, H1 2012

World Therapy: Fibromyalgia – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Fibromyalgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

World Therapy: Choroidal Neovascularization – Pipeline Review, H1 2012

World Therapy: Choroidal Neovascularization – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Choroidal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...

Hyperglycemia - Pipeline Review, H1 2014

Hyperglycemia - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

Hyperglycemia - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Hyperglycemia - Pipeline Review, H1 2014', provides an overview of the Hyperglycemia's therapeutic pipeline. This report provides ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.